July 2020 Vol 11, No 7
Telehealth continues to play a critical role in providing healthcare services to patients during the COVID-19 pandemic. In a webcast titled COVID-19: Impact on Telehealth, Rick Lee, Executive Chairman, Healthy Platforms and CancerLife, along with a panel of experts, discussed the benefits and ongoing challenges associated with the use of telemedicine and the far-reaching impact of this technology beyond the current crisis.
The federal government is an active participant in shaping healthcare policy and delivering care. The panelists in this session addressed the government’s response to COVID-19 and weighed in on some of the issues that their agencies frequently encountered as medical practices grapple with the new normal.
We are living in a time that is filled with multiple challenges. I want to bring
to your attention that the Academy of Oncology Nurse & Patient Navigators
(AONN+) has created a virtual toolkit of information for our membership regarding
the COVID-19 pandemic.
At the 2020 virtual meeting of the American Association
for Cancer Research (AACR), a group
of oncologists working in different hot spots
around the world gave a snapshot of wisdom gleaned
from their experience thus far.
The authors advocate for nurse navigation services to guide patients through this challenging time in their lives.
On May 15, 2020, the FDA approved a new indication for the first immunotherapy combination with the PD-1 inhibitor nivolumab (Opdivo; BMS) and the CTLA-4 inhibitor ipilimumab (Yervoy; BMS) for the first-line treatment of adults with metastatic non–small-cell lung cancer (NSCLC) and PD-L1 expression of ≥1%, as determined by an FDA-approved test, but without EGFR or ALK genomic translocations.
Data from the TRACERx lung study suggest that
circulating tumor DNA (ctDNA) may be a
biomarker for the detection of postsurgical minimal
residual disease (MRD) in patients with non–small-cell lung cancer (NSCLC), suggesting which
patients are at higher risk of relapse and require more
aggressive adjuvant therapy.
Exploring second opinions allows patients to become more informed and secure in their choice of which treatment to pursue.
A bispecific chimeric antigen receptor (CAR)
T-cell product directed against CD19 and CD22
antigens induced a complete response (CR) in 5
of 12 (42%) evaluable children and young adults with
relapsed/refractory acute lymphoblastic leukemia (ALL)
or non-Hodgkin lymphoma.
The first off-the-shelf chimeric antigen receptor
(CAR) T-cell platform targeting CD7 induced a
complete response (CR) with no minimal residual
disease (MRD) in 4 of the first 5 adults with adult relapsed/
refractory T-cell acute lymphoblastic leukemia
(T-ALL) who were treated with the universal CAR
T-cell therapy known as GC027.
The combination of the checkpoint
inhibitor durvalumab, the PARP
inhibitor olaparib, and the taxane
paclitaxel as neoadjuvant therapy improved
pathological complete response
(pCR) compared with physician’s choice
of chemotherapy in high-risk HER2-negative
stage II or III breast cancer.
The combination of the checkpoint
inhibitor atezolizumab plus the
BRAF inhibitor vemurafenib and
the MEK inhibitor cobimetinib improved
progression-free survival (PFS) and lengthened
duration of responses compared with
the 2 targeted therapies plus placebo in
newly diagnosed BRAF V600E/K–mutant
advanced melanoma, according to results
of the phase 3 IMspire150 trial presented
at the 2020 virtual meeting of the American
Association for Cancer Research.
The Academy of Oncology Nurse
& Patient Navigators (AONN+)
is pleased to announce the launch
of a national committee addressing community
outreach, prevention, and early
detection.
Results 1 - 13 of 13